Huadong Medicine Co., Ltd. (SHE: 000963) announced that the marketing application for Conveglipron Trometamol Tablets (development code: HDM1002 tablets) for long‑term weight control in adults has been accepted by China’s National Medical Products Administration (NMPA) — advancing an orally administered, once‑daily small‑molecule GLP‑1 receptor agonist with global intellectual property rights, backed by a pivotal Phase III trial in which all dose groups met all primary and key secondary endpoints at Week 44 with weight loss continuing through Week 52.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Action | Acceptance of marketing application |
| Product | Conveglipron Trometamol Tablets (development code: HDM1002 tablets) |
| Modality | Oral small‑molecule GLP‑1 receptor agonist, once daily |
| Proposed Indication | Long‑term weight control in adults, as an adjunct to a reduced‑calorie diet and increased physical activity |
| Eligible Population | Initial BMI ≥28 kg/m² (obesity), or ≥24 kg/m² (overweight) with at least one weight‑related comorbidity (e.g., hypertension, dyslipidemia, hyperuricemia, abnormal glucose metabolism, fatty liver, cardiovascular disease) |
| Announcement Date | 2 Nov 2026 |
| Developer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (Zhongmei Huadong), subsidiary of Huadong Medicine |
| Intellectual Property | Independently developed; global IP rights held |
Drug Profile & Dosing Advantages
- Molecule: Conveglipron Trometamol (HDM1002) — an oral small‑molecule glucagon‑like peptide‑1 (GLP‑1) receptor agonist, independently developed by Zhongmei Huadong.
- Route Revolution: Once‑daily oral tablet delivery offers a needle‑free alternative to injectable GLP‑1 therapies — a decisive convenience advantage for chronic weight management.
- No Fasting Restriction: Absorption is unaffected by food and water intake, requiring no strict fasting conditions or post‑dose waiting time — a key differentiator versus existing oral GLP‑1 peptides that demand empty‑stomach dosing with water restrictions.
- Compliance Design: The flexible, convenient dosing profile is engineered to support long‑term adherence, the central challenge in chronic weight‑control therapy.
- Global Rights: Huadong Medicine holds worldwide intellectual property rights, preserving out‑licensing and international development optionality.
Clinical Evidence – Pivotal Phase III HDM1002‑301
| Endpoint Category | Result |
|---|---|
| Study Design | Multicenter, randomized, double‑blind, placebo‑controlled, parallel‑design pivotal Phase III trial in overweight or obese adults (study number: HDM1002‑301) |
| Primary & Key Secondary Endpoints (Week 44) | All dose groups met all primary endpoints and key secondary endpoints |
| Durability | Weight‑loss effects continued through Week 52, with no weight‑loss plateau observed |
| Cardiometabolic Benefits | Significant improvements in multiple cardiometabolic indicators |
| Liver Fat | Substantial reduction in liver fat content |
| Body Composition | Optimization of body composition observed |
| Safety | Good safety and tolerability |
Specific numeric efficacy values (e.g., percent weight reduction by dose group) were not disclosed in the announcement.
Pipeline Expansion & Market Impact
- Type 2 Diabetes Program: Beyond weight management, Phase III clinical trials in China of Conveglipron Trometamol Tablets for type 2 diabetes are ongoing — a second major indication for the same molecule.
- Oral GLP‑1 Race: HDM1002 positions Huadong Medicine in the intensifying global competition to deliver convenient oral GLP‑1 agonists, targeting the vast primary‑care weight‑management population underserved by injectables.
- China BMI Criteria Fit: The proposed label aligns with Chinese BMI cut‑offs (≥28 obesity; ≥24 overweight), reflecting a domestically tailored regulatory strategy for the large Chinese overweight and obese population.
- Metabolic Breadth: Improvements in cardiometabolic indicators, liver fat reduction, and body composition optimization extend the value proposition beyond scale weight — relevant to comorbid conditions enumerated in the proposed indication.
- Pre‑Approval Stage: Marketing application acceptance initiates NMPA technical review; approval timing and final label are subject to regulatory evaluation.
- Watch Items: NMPA review progression and potential approval decision, type 2 diabetes Phase III readouts, commercial launch planning, and competitive dynamics among oral GLP‑1 entrants in China.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory review, potential approval, commercialization, and indication expansion of Conveglipron Trometamol Tablets (HDM1002). Acceptance of a marketing application does not guarantee approval or the final approved label. Actual results may differ due to risks including regulatory review outcomes, safety and efficacy findings upon full data evaluation, competitive dynamics in the GLP‑1 receptor agonist class, pricing and reimbursement negotiations, and launch execution.-Fineline Info & Tech
